New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...
Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for a new cardiovascular risk reduction claim, as it faces increased competition from Novo Nordisk. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results